Pharmacokinetics and pharmacodynamics of immunosuppressive drugs in elderly kidney transplant recipients
- 1 October 2015
- journal article
- research article
- Published by Elsevier BV in Transplantation Reviews
- Vol. 29 (4), 224-230
- https://doi.org/10.1016/j.trre.2015.04.007
Abstract
No abstract availableFunding Information
- Astellas Pharma
- Bristol-Myers Squibb
- Sichuan University
This publication has 100 references indexed in Scilit:
- Kidney Transplantation in the Older AdultAmerican Journal of Kidney Diseases, 2013
- Induction Immunosuppressive Therapy in the Elderly Kidney Transplant Recipient in the United StatesClinical Journal of the American Society of Nephrology, 2011
- Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 ExpressionAmerican Journal of Transplantation, 2010
- Prolonged Graft Survival in Older Recipient Mice Is Determined by Impaired Effector T-Cell but Intact Regulatory T-Cell ResponsesPLOS ONE, 2010
- Immunotherapy in Elderly Transplant RecipientsDrugs & Aging, 2009
- A Population Pharmacokinetic Model of Ciclosporin Applicable for Assisting Dose Management of Kidney Transplant RecipientsClinical Pharmacokinetics, 2009
- Age, model for end-stage liver disease score, and organ functioning predict posttransplant tacrolimus neurotoxicityLiver Transplantation, 2008
- T cell subset-specific susceptibility to agingClinical Immunology, 2008
- A Bayesian approach for population pharmacokinetic modelling of sirolimusBritish Journal of Clinical Pharmacology, 2005
- Drug Dosage in the ElderlyDrugs & Aging, 1998